Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bladder cancer, 1996

D L Lamm1, F M Torti

  • 1Department of Urology, Robert C. Byrd Health Sciences Center of West Virginia University, Morgantown, USA.

CA: a Cancer Journal for Clinicians
|March 1, 1996
PubMed
Summary

Superficial bladder cancer treatments like intravesical chemotherapy and BCG immunotherapy show significant efficacy in eradicating tumors and reducing recurrence. Advanced and metastatic bladder cancers also show promise with neoadjuvant, adjuvant, and combination chemotherapy regimens.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Iron addiction: a novel therapeutic target in ovarian cancer.

Oncogene·2017
Same author

Effects of Anti-repulsive Guidance Molecule C (RGMc/Hemojuvelin) Antibody on Hepcidin and Iron in Mouse Liver and Tumor Xenografts.

Clinical & experimental pharmacology·2017
Same author

Heat localization for targeted tumor treatment with nanoscale near-infrared radiation absorbers.

Physics in medicine and biology·2012
Same author

The core control system of intracellular iron homeostasis: a mathematical model.

Journal of theoretical biology·2012
Same author

Standardization in pathologic assessment of transitional cell cancer of the bladder.

Urologic oncology·2011
Same author

Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study.

Urologic oncology·2011

Area of Science:

  • Urology
  • Oncology
  • Cancer Research

Background:

  • Superficial bladder cancer (Ta/T1) has a high recurrence rate, necessitating effective treatments.
  • Intravesical chemotherapy and Bacillus Calmette-Guérin (BCG) immunotherapy are established treatments for superficial bladder cancer.
  • Muscle-invasive and metastatic bladder cancers present significant treatment challenges.

Purpose of the Study:

  • To review the efficacy of various intravesical and systemic treatments for different stages of bladder cancer.
  • To evaluate the role of chemotherapy and immunotherapy in reducing tumor recurrence, progression, and mortality.
  • To identify areas for further research in bladder cancer treatment.

Main Methods:

  • Review of existing data on intravesical chemotherapy and BCG immunotherapy for superficial bladder cancer.
  • Analysis of neoadjuvant and adjuvant chemotherapy regimens for locally advanced and muscle-invasive bladder cancer.
  • Evaluation of combination chemotherapy (CMV, M-VAC) for metastatic bladder cancer.

Main Results:

  • Intravesical chemotherapy eradicates tumors in 33-50% and reduces recurrence by 12-15%.
  • BCG immunotherapy eradicates tumors in up to 90% and reduces recurrence by 40%, with long-term survival benefits.
  • Neoadjuvant chemotherapy shows promise for locally advanced disease; adjuvant chemotherapy and combination regimens for metastatic disease can lead to long-term survivors.

Conclusions:

  • Intravesical chemotherapy and BCG immunotherapy are highly effective for superficial bladder cancer.
  • Chemotherapy plays a crucial role in neoadjuvant, adjuvant, and metastatic settings, though further research is needed.
  • Optimizing treatment strategies for advanced bladder cancer is essential to increase long-term survival rates.

Related Experiment Videos